China SXT Pharmaceuticals, Inc. (SXTC) Net margin 2017–2026
China SXT Pharmaceuticals, Inc. (SXTC) net profit margin by fiscal year — reported net income divided by reported revenue.
-545.2%FY2026 · since FY2017: 24.3% → -545.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -545.2% | -355.5 pp |
| FY2025 | -189.8% | -29.1 pp |
| FY2024 | -160.7% | +140.3 pp |
| FY2023 | -301.0% | -80.6 pp |
| FY2022 | -220.4% | -162.9 pp |
| FY2021 | -57.5% | +141.8 pp |
| FY2020 | -199.3% | -221.2 pp |
| FY2019 | 22.0% | +5.0 pp |
| FY2018 | 16.9% | -7.4 pp |
| FY2017 | 24.3% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More SXTC financial trends
SXTC RevenueSXTC Net incomeSXTC Gross profitSXTC Gross marginSXTC Operating incomeSXTC Operating marginSXTC Operating cash flowSXTC Free cash flowSXTC Capital expendituresSXTC Return on equitySXTC Stock buybacksSXTC Dividends paidSXTC Total assetsSXTC Total liabilitiesSXTC Shareholders’ equitySXTC overview →